Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lyra Therapeutics (LYRA) Shares Outstanding (Diluted Average) (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed Shares Outstanding (Diluted Average) for 5 consecutive years, with $1.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 36.03% to $1.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.8 million, a 36.03% increase, with the full-year FY2024 number at $65.1 million, up 30.74% from a year prior.
  • Shares Outstanding (Diluted Average) was $1.8 million for Q3 2025 at Lyra Therapeutics, up from $1.3 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $65.8 million in Q1 2025 to a low of $1.3 million in Q3 2024.
  • A 5-year average of $28.4 million and a median of $30.2 million in 2022 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): surged 183.72% in 2022, then plummeted 97.17% in 2024.
  • Lyra Therapeutics' Shares Outstanding (Diluted Average) stood at $13.0 million in 2021, then skyrocketed by 132.83% to $30.2 million in 2022, then skyrocketed by 64.72% to $49.8 million in 2023, then soared by 30.74% to $65.1 million in 2024, then plummeted by 97.29% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Shares Outstanding (Diluted Average) are $1.8 million (Q3 2025), $1.3 million (Q2 2025), and $65.8 million (Q1 2025).